Multibagger Selection: Muse Spark 1.1's picks
Muse Spark 1.1 picked LUNR, ACHR, VERA, ENVX, SMR with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | LUNR | — | 72% | — | — |
| 2 | ACHR | — | 68% | — | — |
| 3 | VERA | — | 75% | — | — |
| 4 | ENVX | — | 65% | — | — |
| 5 | SMR | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +10.12% | +10.17% | 1.45x | 0 |
The model's market view
Small and mid-cap environment in October 2026 is bifurcated: large-cap AI capex is compressing free cash flow, while select sub-$5B companies with verifiable commercial inflections (space launch, eVTOL certification, biotech launch, battery ramp, SMR licensing) trade 60-80% below 2025 highs, leaving room for extreme repricing if execution hits. Dollar volume remains high despite price drawdowns, satisfying liquidity.
Why each pick
LUNR
Intuitive Machines has TTM revenue $490.12M with 3Y CAGR 138.09% and backlog driven by NASA CLPS. Stock down from $46.75 high to $10.98, market cap $2.47B. Gross margin 16.3% but improving via higher-margin data services. Company guides to positive free cash flow as lunar lander cadence increases. Valuation at 7x sales vs space peers at 12-15x leaves room for 3x if mission success and contract conversion materialize.
ACHR
Archer Aviation trades at $3.13B market cap, down 65.39% over 1 year, with $7M TTM revenue pre-certification. FAA Type Certification for Midnight eVTOL expected H2 2027 with final compliance flights in 2026-2027. Partnership with United Airlines for commercial routes and Stellantis manufacturing capacity provides credible commercialization path. Cash ~$400M post recent raises extends runway through certification.
VERA
Vera Therapeutics received FDA accelerated approval for TRUTAKNA atacicept on July 7 2026 for IgA nephropathy. Market cap $2.01B at $30.55 per share, down from $56 high. Commercial launch mid-2026 with $714.6M cash as of Dec 31 2025 funding launch. Gross margin for biologics >80% expected. Catalyst is ORIGIN 3 final eGFR readout at ASN Kidney Week Oct 22 2026 and conversion from accelerated to full approval.
ENVX
Enovix market cap $546.43M down 80.13% over 1 year, price $2.355, 52-week low $2.35. TTM revenue ~$32M but Fab2 in Malaysia ramping to produce 100% silicon anode batteries for smartphones. Customer is undisclosed Tier 1 smartphone OEM, with commercial shipments guided H1 2027. Gross margin currently negative but expected to inflect to 30%+ at scale. Valuation leaves room for 3x if Tier 1 order confirmed.
SMR
NuScale Power market cap $2.51B down 85.57% over 1 year, price $5.535, near 52-week low $5.44. Only NRC-approved SMR design in US (US460 approved May 2025). Revenue collapsed 99% to $75K Q2 2026 as Romania FEED completed, but catalyst is TVA ENTRA1 power purchase agreement and Romania 6-module FID expected end 2026. If PPA signed, stock could re-rate as first commercial SMR order in US.
Other models on the same run
| Model | Picks |
|---|---|
| Perplexity | PGY, AEHR, MAZE, AAPG, RGTI |
| Gemini 3 Pro | LUNR, RDW, SOUN, ACMR, RGTI |
| Claude Opus 5.5 | RCAT, LPTH, ONDS, AEHR, CAPR |
| DeepSeek | INOD, RZLV, FEIM, PVLA, AGIO |
| Grok 4.5 | INOD, NRIX, PVLA, CALX, FEIM |
| GPT-6 | BKSY, AMPX, RCAT, RDW, EOSE |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.